QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 metsera-reports-up-to-14-weight-loss-in-phase-2b-obesity-trial

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global P...

Core News & Articles

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateauPotential for best-in-class tolerability with min...

Core News & Articles

Leerink Partners analyst David Risinger downgrades Metsera (NASDAQ:MTSR) from Outperform to Market Perform and lowers the pr...

 pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-matsera-deal

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to ...

Core News & Articles

- Reuters Cites Conf Call

 metsera-stock-surges-over-60-in-monday-pre-market-as-pfizer-reportedly-nears-acquisition-deal-pfe-stock-up-15

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metser...

Core News & Articles

Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement u...

Core News & Articles

https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac

Core News & Articles

Leerink Partners analyst David Risinger initiates coverage on Metsera (NASDAQ:MTSR) with a Outperform rating and announces P...

Core News & Articles

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Metsera (NASDAQ:MTSR) from Overweight to Overweight.

Core News & Articles

B of A Securities analyst Tim Anderson maintains Metsera (NASDAQ:MTSR) with a Buy and raises the price target from $45 to $50.

Core News & Articles

Metsera (NASDAQ:MTSR) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.64) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION